AbbVie steps into the obesity drug race, licensing medicine from Danish firm

The obesity medicine field has gained a new entrant, with AbbVie on Monday announcing it had licensed an experimental weight loss drug from a Danish company that is in a Phase 1 trial.

The deal includes a $350 million upfront payment to the company, Gubra, for the rights to its drug, called for now GUB014295. AbbVie will pay up to some $1.9 billion if certain development and sales milestones are met.

The agreement comes less than a year since Robert Michael took over as CEO of AbbVie and as the company looks for its next top-selling drugs following the loss of patent protection for its mega blockbuster autoimmune treatment Humira. In a statement, Michael said that the Gubra partnership offers “a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company.”

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Use of blood fat-lowering statins linked to slower progression of Alzheimer’s dementia

Blood fat-lowering statins could slow the progression of Alzheimer’s disease, at least for some patients. This is the result of a new study led by

December 20, 2023

How the world’s biggest pharma and biotech companies paid their typical worker in 2023

Among the biopharma industry’s biggest employers, California’s Gilead Sciences had the highest median salary for its workforce, an Endpoints News analysis found. Endpoints tallied 2023

July 11, 2024

New global guideline for Candida infections sets standards for diagnosis and treatment

Together with a team of international clinical researchers, Professor Dr Oliver A. Cornely and Dr Rosanne Sprute from University Hospital Cologne have published the new

February 15, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.